Holen Sie sich die Stockscreener-App
137.45
0.98%
-1.36
Handel nachbörslich:
137.69
0.24
+0.17%
Schlusskurs vom Vortag:
$138.81
Offen:
$138.19
24-Stunden-Volumen:
1.20M
Relative Volume:
1.75
Marktkapitalisierung:
$8.35B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
19.36
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
-1.98%
1M Leistung:
+11.29%
6M Leistung:
+28.34%
1J Leistung:
+16.95%
1-Tages-Spanne:
$136.48
$140.27
1-Wochen-Bereich:
$135.36
$142.93
52-Wochen-Spanne:
$99.06
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
137.45 | 8.35B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
HC Wainwright Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
Insider Sell: Bruce Cozadd Sells 6,500 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus.com
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga India
Victory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group - Defense World
Robert Iannone Sells 7,080 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock - Defense World
Morgan Stanley Reiterates “Overweight” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $230.00 - Defense World
UBS Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq
Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145 - Marketscreener.com
UBS raises Jazz Pharmaceuticals stock rating to Buy, target to $179 By Investing.com - Investing.com UK
Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells 4,813 Shares of Stock - MarketBeat
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Yahoo Finance
Jazz Pharmaceuticals at TD Cowen Conference: Strategic Growth in Focus By Investing.com - Investing.com UK
Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart
Truist lifts Jazz Pharma stock target to $230 on promising pipeline - Investing.com UK
Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating - Marketscreener.com
Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN
Jazz Seeks To Augment Rare Cancer Portfolio With Chimerx Buyout - News & Insights
Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada
Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld Online
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX, - Barchart
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz - BioCentury
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX, - Nasdaq
A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts - Benzinga
Executive VP & Chief Legal Officer Neena Patil Sold A Bunch Of Shares In Jazz Pharmaceuticals - Simply Wall St
Jazz Buys ChimerixA Good Deal To Make With Major Approval Catalyst In Play - Seeking Alpha
3 Firms Build Jazz Pharmaceuticals' $935M Chimerix Buy - Law360
Jazz Pharmaceuticals bids for Chimerix in $935m deal - Pharmaceutical Technology
Jazz expands in oncology with $935M deal for Chimerix - BioPharma Dive
Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says - Marketscreener.com
Jazz Pharmaceuticals plc entered into a definitive agreement to acquire Chimerix, Inc. for approximately $930 million. - Marketscreener.com
Jazz Pharma aims to boost cancer drug pipeline with $935 million buyoutSan Francisco Business Times - The Business Journals
Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals - TipRanks
Jazz Pharmaceuticals Acquires Chimerix In $935 Million Deal - Finimize
Jazz Pharmaceuticals to buy Chimerix for $935 million - MLex
Jazz Pharmaceuticals to Acquire Chimerix for $935M - Contract Pharma
Jazz Pharmaceuticals buys Chimerix for $935 million - Green Market Report
Jazz Pharmaceuticals To Acquire Chimerix For $935 Million - citybiz
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga
Jazz Pharmaceuticals to Acquire Chimerix in $935M Deal - TipRanks
Jazz Pharmaceuticals to acquire Chimerix for $935 million - Investing.com India
Jazz Pharmaceuticals to buy Chimerix for $935 million -March 05, 2025 at 07:28 am EST - Marketscreener.com
Chimerix stock gains on Jazz Pharma bid (JAZZ:NASDAQ) - Seeking Alpha
Jazz Pharmaceuticals to Buy Chimerix for Roughly $935 Million -March 05, 2025 at 07:09 am EST - Marketscreener.com
JAZZ (JAZZ) to Acquire Chimerix (CMRX) for $8.55/sh Cash - StreetInsider.com
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
8.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):